Clinical Trials Browser

Phase 3 × Completed × Metastatic Hormone Sensitive Prostate Cancer × Clear all

NCT02677896 2025-10-24

ARCHES

Phase 3 Completed

1,150 enrolled 23 charts 1 FDA

Metastatic Hormone Sensitive Prostate Cancer